Cardiology

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

New research highlights significant declines in cardiovascular screenings for U.S. adults with disabilities during the COVID-19 pandemic, revealing ongoing healthcare disparities.

Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.

Actual LLT use was significantly lower than the proportion of guideline-eligible patients for statins, ezetimibe, and PCSK9i.

New data from a UMichigan survey found that 8% of preventative aspirin users had not even discussed their use with any health care provider.

This study highlights the rate of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use for heart failure within US ambulatory cardiovascular care settings.

Discover how structured routines and exercise enhance mental health for those with bipolar disorder, fostering stability, and community support.

The prespecified analysis of FINEARTS-HF found finerenone’s impact on HF events, cardiovascular death, and symptoms was not impacted by frailty.

Based on 8 major questions and consisting of 9 formal recommendations, the SCAI’s guidelines aim to advise clinicians on what treatments to use when.

Our recap of Q2 2025 in cardiology spotlights 3 FDA headlines, trial news, and new episodes of Don't Miss a Beat.

According to recent research, more patients surviving heart diseases correlates directly to higher mortality rates for ischemic and chronic heart conditions.

Our June 2025 recap highlights significant advancements in cardiology, including new drug approvals and pivotal trial results.

The results of the ZENITH trial have encouraged the expansion of sotatercept’s label to patients with prior background therapy.

The Phase 3 HYPERION trial achieved its primary endpoint of lower time to clinical worsening, measured by a variety of related factors.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

Findings highlight an increased risk of MASLD, heart failure, type 2 diabetes, and other cardiometabolic diseases following cycles of weight loss and regain.

GMRx2 is now the first and only FDA-approved triple combination medication for use as an initial therapy in patients needing multiple drugs to lower blood pressure.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.

By targeting insulin resistance at its source, dual receptor agonists may have a more efficient method of tackling the growing obesity problem, as well as its cardiovascular effects.

Potentially the first successful CETP inhibitor, obicetrapib has shown positive trial results in reducing the risk of cardiovascular disease when combined with statins.

Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

With so many new medications ostensibly filling the niche typically occupied by ACE/ARBs, are the medications practically useful in a changed treatment landscape?